Drug Trial Radar · NCT03013543
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Last checked: Nov 19, 2026Latest source record: Aug 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Feb 10, 2017
Primary completion
Mar 1, 2022
Study completion Mar 1, 2022
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.
Conditions
- Genetic Obesity
- Obesity
- Obesity Due to Melanocortin 4 Receptor Deficiency
Interventions
SetmelanotideDrug
RM-493 QD SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide TreatmentTime frame: Baseline to Month 3
Locations
58 sites in 9 countries. Site status is shown where the registry gives one.
Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC
Birmingham, Alabama
Synexus Clinical Research US, Inc. - Phoenix Southeast
Chandler, Arizona
Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC
Mesa, Arizona
Honor Health Research Institute
Scottsdale, Arizona
Axis Clinical Trials-Downtown
Los Angeles, California
Axis Clinical Trials Headquarters
Los Angeles, California
San Diego Wake Research
San Diego, California
Anschutz Health and Wellness Center University of Colorado Anschutz Medical Campus
Aurora, Colorado
Division of Endocrinology and Diabetes Children's National Hospital
Washington D.C., District of Columbia
University of Florida College of Medicine
Gainesville, Florida
AXIS South Florida Clinical Trials
Hialeah, Florida
Florida Hospital
Orlando, Florida
Synexus Clinical Research US, Inc. - St. Petersburg
Pinellas Park, Florida
Synexus Clinical Research US, Inc. - Chicago
Chicago, Illinois
Maine Medical Partners
Portland, Maine
NIH Hatfield Clinical Research Center
Bethesda, Maryland
Baystate Medical Center
Springfield, Massachusetts
University of Michigan Medicine
Ann Arbor, Michigan
Precision Medicine for Obesity Research: Gastroenterology & Hepatology Mayo Clinic
Rochester, Minnesota
Washington University St. Louis
St Louis, Missouri
Impact Clinical Trials
Las Vegas, Nevada
AXIS New York Clinical Trials
Brooklyn, New York
University at Buffalo
Buffalo, New York
AXIS Clinical Trials
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University
New York, New York
Duke University Medical Center
Durham, North Carolina
Wake Research Inc.
Raleigh, North Carolina
Synexus Clinical Research US, Inc. - Akron
Akron, Ohio
Synexus Clinical Research US, Inc. - Cincinnati
Cincinnati, Ohio
Synexus Clinical Research US, Inc. - Columbus
Columbus, Ohio
Obesity Institute, Geisinger Clinic
Danville, Pennsylvania
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
Synexus Clinical Research US, Inc. - Primary Care Associates, PC
Anderson, South Carolina
Wake Research TN
Chattanooga, Tennessee
Le Bonheur Children's Hospital
Memphis, Tennessee
Vanderbilt University School of Medicine
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Synexus Clinical Research US, Inc. - Plano
Plano, Texas
Synexus Clinical Research US, Inc. - San Antonio
San Antonio, Texas
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.